In the News
MIT Technology Review June 6, 2017
Dan Rhodes, Strata's co-founder and CEO, comments on the need to provide cancer patients broad access to tumor profiling to identify those who will benefit from targeted therapy drugs.
MedCity News May 24, 2017
Dr. Scott Tomlins, Strata's co-founder and Laboratory Director, comments on the accelerated approval of Keytruda for MSI-H and dMMR cancers and the opportunity to accelerate the approval of additional precision therapies in biomarker-defined patient populations. At Strata Oncology, we believe that by institutionalizing tumor sequencing and clinical trial participation across a large network of hospitals, we can help usher in the next wave of biomarker-guided precision medicine approvals.
Nature Biotechnology Sept. 8, 2016
MIT Technology Review June 14, 2016
To match cancer patients with drugs, one company plans to offer free genetic tests.
FierceBiotech Jun 6, 2016
Xconomy Jun 6, 2016